Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
Back to Search Results

Connection

Search Results to Laura Hutchins

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following items that are connected to Hutchins, Laura

Item TypeName
Academic Article Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer.
Academic Article Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897.
Academic Article Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026.
Academic Article Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.
Academic Article A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in a 3-times-daily regimen to treat patients with recurrent metastatic breast cancer.
Academic Article Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma.
Academic Article Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508.
Academic Article Phase 2 trial of Allovectin-7 in advanced metastatic melanoma.
Academic Article Phase II trial of topotecan by continuous infusion in patients with advanced soft tissue sarcomas, a SWOG study. Southwest Oncology Group.
Concept Clinical Trials, Phase III as Topic
Concept Clinical Trials, Phase I as Topic
Concept Clinical Trials, Phase II as Topic
Academic Article A Phase II Study of High-Dose Allovectin-7 in Patients with Advanced Metastatic Melanoma
Academic Article A US Multicenter Phase II Trial of Navelbine in Advanced Breast Cancer
Academic Article Phase I/II trial of High Dose Cytoxan, Continuous Infusion Vincristine, Escalating Doses of BP-16 and TBI with Autologous Bone Marrow Transplants (ABMT)
Academic Article A Controlled, Randomized Phase III Trial Comparing the Response to Dacarbazine With and Without Allovectin-7(A) in Patients with Metastatic Melanoma
Academic Article Phase II trial of elesclomol (formerly STA-4783) and paclitaxel in stage IV metastatic melanoma (MM): Subgroup analysis by prior chemotherapy
Academic Article Phase I Clinical Trial of Tamoxifen and Interferon Alpha in the Treatment of Solid Tumors
Academic Article The Efficacy of Thalidomide and Irinotecan in Metastatic Colorectal Carcinoma (Phase II Study)
Academic Article Phase II trial of biochemotherapy with interferon alpha, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial
Academic Article 2-year overall survival (OS) results of a phase II trial of elesclomol (formerly STA-4783) and paclitaxel in stage IV metastatic melanoma (MM)
Academic Article Update of the NCI multiinstittutional phase II trial of romidepsin, FK228, for patients with cutaneous or peripheral T-cell lymphoma
Academic Article SWOG 9518: Phase II Trial of Continuous Infusion Topotecan in Patients (PTS) with Advanced Soft Tissue Sarcomas (STS)
Academic Article Phase I Clinical Trial of Tamoxifen and Interferon Alpha in the Treatment of Solid Tumors
Academic Article Irinotecan and Thalidomide in Metastatic Colorectal Cancer: Preliminary Results of a Phase II Study
Academic Article Phase II Trial of HLA-B7 Plasmid DNA/LIPID (Allovectin-7) Immunotherapy in Patients with Metastatic Melanoma (MM) Univ. of Colorado, Denver. Allovectin-7 Phase II Study Group and Vical Incl, San Diego, CA
Academic Article Subgroup analysis of efficacy and safety analysis of a randomized, double-blinded controlled phase II study of STA-4783 in combination with paclitaxed in patients with metastatic melanoma
Academic Article Trigem Anti-idiotype (Anti-Id) Monoclonal Antibody (MAb) Treatment for Stage III Melanoma: Results of a Multicenter Phase II Trial
Academic Article Phase II trial of combination thalidomide (thal) plus temozolomide (TMZ [TT]), in patients with metastatic malignant melanoma (MMM): Southwest Oncology Group S0508
Academic Article A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3.
Academic Article Germline Genetic Variants in TEK, ANGPT1, ANGPT2, MMP9, FGF2 and VEGFA Are Associated with Pathologic Complete Response to Bevacizumab in Breast Cancer Patients.
Academic Article Managing Expectations in the Transition to Proof of Concept Studies.
Academic Article Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma.
Academic Article Targeting tumor-associated carbohydrate antigens: a phase I study of a carbohydrate mimetic-peptide vaccine in stage IV breast cancer subjects.
Grant SOUTHWEST ONCOLOGY GROUP
Grant Expanding Translational Research in Arkansas
Grant CFDA # 93.395SWOG 0709,Federal funding- A PHASE II SELECTION DESIGN OF PHARMACODYNAMIC SEPARATION OF CARBOPLATIN/PACLITAXEL/ERLOTINIB OR ERLOTINIB ALO
Grant A Phase II Open Label Single-Arm Study of E7389 in Patients with Locally Advanced or Metastatic Breast Cancer, Previously Treated with Anthracycline,
Grant UARK 2004-26 (P03267-10) Extended Schedule, Escalated Dose Temozolomide versus Dacarbazine in Stage IV Metastatic Melanoma: A Randomized Phase III St
Grant S1115, Randomized Phase II Clinical Trial of AZD6244 Hydrogen Sulfate (NSC-748727) and MK-2206 (NSC-749607) VS mFOLFOX in Patients with Metastatic Pan
Grant UARK 2002-02, A Phase III Randomized Double-Blind Trial of Immunotherapy with a Polyvalent Melanoma Vaccine, CancerVax Vaccine, plus BCG versus Placeb
Grant CTSU E2607 A Phase II Trial of Dasatinib in KIT-Positive Patients with Unresectable Locally Advanced or Stage IV Mucosal, Acral and Vulvovaginal Melan
Grant SWOG 0925, A Randomized Phase II Study of Androgen Deprivation Combined with IMC-A12 Versus Androgen Deprivation Alone for Patients with New Hormone-S
Grant SWOG 0819, A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel Or Carboplatin/Paclitaxel/Bevacizumab With Or Without Concurrent Cetuximab i
Grant Protocol H8K-MC-JZAO A Randomized Phase 3 Study of Tasisulam Administered as an Intravenous Infusion on Day 1 of a 28 Day Cycle vs. Paclitaxel as Seco
Grant UARK 2002-01 A Phase III Randomized Double-Blind Pivotal Trial of Immuntherapy with BCG plus a Polyvalent Melanoma Vaccine, CancerVax Vaccine, versus
Grant A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients wi
Grant A Phase II, Multicenter, Open Label Study of YM155 in Subjects with Unresectable Stage III or Metastatic (Stage IV) Melanoma as First-Line Therapy
Grant SWOG 0826, A PHASE II TRIAL OF SCH 727965 (NSC 747135) IN PATIENTS WITH STAGE IV MELANOMA
Grant SWOG 1005, “A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer”
Grant SWOG 0931, EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, a Phase III Study
Grant SWOG 0802, A Randomized Phase II Trial Of Weekly Topotecan With And Without AVE0005 (Aflibercept; NSC-724770) In Patients With Platinum Treated Extens
Grant Protocol CA184-008 A Multi-center Single Arm Phase II Study of MDX-010 (BMS 734016) Monotherapy in Patients with Previously Treated Unresectable Stag
Grant Phase 2 Open-Label, Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability and Pharmakokinetics of CP-675-206 in pts w/ Adv Refractory /
Grant S1201, A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1 (Excision Repair Cross-Complementing 1) for Ad
Grant A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 ASCI as adjuvant therapy in patients with M
Grant UARK 2005-33: Phase 3, open label, randomized comparative study of ticilimumab and either dacarbazine or temozolomide in patients with advanced melano
Grant A Phase III Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel with or without the PARP Inhibitor Verliparib (ABT-888) in Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer
Grant SWOG 0800, A Randomized Phase II Trial of Weekly Nanoparticle Albumin Bound Paclitaxel (Nab-Paclitaxel) (NSC-736631) With or Without Bevacizumab, Eith
Grant SWOG 0910, A Phase II Study of Epratuzumab (NSC-716711) in Combination with Cytarabine and Clofarabine for Patients with Relapsed or Refractory Ph-Neg
Grant SWOG 1320, A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) And Trametininb (NSC-763093) in BRAFV600E/K MUTANT MELANOMA
Grant “A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination with Temozolomide or Veliparib in Combination with Carboplat
Grant SWOG 0622 Phase II Studies of Two Different Schedules of Dasatinib (NSC-732517) in Bone-Metastasis Predominant Metastatic Breast Cancer
Grant - SWOG 0919 A PHASE II STUDY OF IDARUBICIN AND ARA-C IN COMBINATION WITH PRAVASTATIN FOR RELAPSED ACUTE MYELOGENOUS LEUKEMIA (AML)
Grant UARK 2002-14, CAL-03: A Phase I-II, 24 Week, Mulitcenter, Double-Blind, Randomized, Dose-Ranging Study to Evaluate the Safety and Efficacy of a Humani
Grant CA033 entitled: “An Open-Label, Multicenter, Phase III Trial of ABI-007 vs. Dacarbazine in Previously Untreated Patients with Metastatic Malignant Mel
Grant ”A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment with OncoVEXGM-CSF Compared to Subcutaneously Administered GM-CS
Grant RSR13 RT-016: A Phase 3 Randomized, Open-Label Comparative Study of Standard Whole Brain Radiation Therapy With Supplemental Oxygen, With or Without C
Grant SWOG 0933, Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Grant SWOG 0230, Phase III Trial Of LHRH Analog Administration During Chemotherapy To Reduce Ovarian Failure Following Chemotherapy In Early Stage, Hormone-
Grant A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment with OncoVEXGM CSF Compared to Subcutaneously Administered GM-CSF
Grant UARK 2002-02, A Phase III Randomized Double-Blind Trial of Immunotherapy with a Polyvalent Melanoma Vaccine, CancerVax Vaccine, plus BCG versus Placeb
Grant UARK 2004-46 (PTH303): Open Label Phase 2 Trial of PT-100 in Patients with Metastatic Melanoma
Grant SWOG 0816, A Phase II Trial of Response Adapted Therapy of Stage III-IV Hodgkin Lymphoma Using Early Interim FDG-PET Imaging
Academic Article Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.
Grant A Phase II, Multicenter, Open Label Study of YM155 in Subjects with Unresectable Stage III or Metastatic (Stage IV) Melanoma as First-Line Therapy
Grant A Phase III Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel with or without the PARP Inhibitor Verliparib (ABT-888) in Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer
Grant SWOG 0910, A Phase II Study of Epratuzumab (NSC-716711) in Combination with Cytarabine and Clofarabine for Patients with Relapsed or Refractory Ph-Neg
Grant Phase 2 Open-Label, Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability and Pharmakokinetics of CP-675-206 in pts w/ Adv Refractory /
Grant SWOG 0933, Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Grant SWOG 0819, A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel Or Carboplatin/Paclitaxel/Bevacizumab With Or Without Concurrent Cetuximab i
Grant SWOG 1005, “A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer”
Grant A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients wi
Grant SWOG 0816, A Phase II Trial of Response Adapted Therapy of Stage III-IV Hodgkin Lymphoma Using Early Interim FDG-PET Imaging
Grant CFDA # 93.395SWOG 0709,Federal funding- A PHASE II SELECTION DESIGN OF PHARMACODYNAMIC SEPARATION OF CARBOPLATIN/PACLITAXEL/ERLOTINIB OR ERLOTINIB ALO
Grant SWOG 0622 Phase II Studies of Two Different Schedules of Dasatinib (NSC-732517) in Bone-Metastasis Predominant Metastatic Breast Cancer
Grant RSR13 RT-016: A Phase 3 Randomized, Open-Label Comparative Study of Standard Whole Brain Radiation Therapy With Supplemental Oxygen, With or Without C
Grant UARK 2004-26 (P03267-10) Extended Schedule, Escalated Dose Temozolomide versus Dacarbazine in Stage IV Metastatic Melanoma: A Randomized Phase III St
Grant SWOG 0800, A Randomized Phase II Trial of Weekly Nanoparticle Albumin Bound Paclitaxel (Nab-Paclitaxel) (NSC-736631) With or Without Bevacizumab, Eith
Grant A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 ASCI as adjuvant therapy in patients with M
Grant S1115, Randomized Phase II Clinical Trial of AZD6244 Hydrogen Sulfate (NSC-748727) and MK-2206 (NSC-749607) VS mFOLFOX in Patients with Metastatic Pan
Grant UARK 2005-33: Phase 3, open label, randomized comparative study of ticilimumab and either dacarbazine or temozolomide in patients with advanced melano
Grant A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment with OncoVEXGM CSF Compared to Subcutaneously Administered GM-CSF
Grant A Phase II Open Label Single-Arm Study of E7389 in Patients with Locally Advanced or Metastatic Breast Cancer, Previously Treated with Anthracycline,
Grant - SWOG 0919 A PHASE II STUDY OF IDARUBICIN AND ARA-C IN COMBINATION WITH PRAVASTATIN FOR RELAPSED ACUTE MYELOGENOUS LEUKEMIA (AML)
Grant SWOG 0230, Phase III Trial Of LHRH Analog Administration During Chemotherapy To Reduce Ovarian Failure Following Chemotherapy In Early Stage, Hormone-
Grant “A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination with Temozolomide or Veliparib in Combination with Carboplat
Grant UARK 2004-46 (PTH303): Open Label Phase 2 Trial of PT-100 in Patients with Metastatic Melanoma

Search Criteria
  • S Phase